Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
+$3.89 today
- Market cap
- $6.04B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
Volume 0.50M
Average 0.95M
MIRM Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Mirum Pharmaceuticals, Inc.NASDAQ: MIRM
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities falls 7.6% from a year ago
Other current liabilities stood at $24.8M at the end of Q2 FY2026, down 7.6% from a year earlier and down 59.5% from the prior quarter. Over 3 fiscal years it compounded at +44.3% a year.
Context
- Other current liabilities amounted to 2.4% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -7.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 47.28M USD
- Year-over-year change
- +46.6%
- 4-year CAGR
- +40.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.28M | +46.6% |
| FY2024 | 2024-12-31 | 32.25M | +54.0% |
| FY2023 | 2023-12-31 | 20.94M | +32.9% |
| FY2022 | 2022-12-31 | 15.75M | +31.4% |
| FY2021 | 2021-12-31 | 11.98M | — |
Other Current Liabilities vs competitors
How MIRM compares with its peers on the latest reported figures
- MIRM's Jun 2026 other current liabilities of $24.8M is the 2nd highest of the 8 companies compared; the peer median is $5.49M.
- Its year-over-year change of -7.6% is the 3rd highest of 6, against a peer median of -13.6%.
- Other current liabilities amounts to 2.4% of total assets for MIRM, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $204.6M | +521.1% | -2.3% | 24.1% | |
| Jun 2026 | $24.8M | -7.6% | +44.3% | 2.4% | |
| Mar 2026 | $17M | -83.1% | — | 1.3% | |
| Mar 2026 | $14.61M | +87.2% | +14.1% | 1.2% | |
| Mar 2026 | $5.49M | -13.6% | +19.8% | 2.2% | |
| Mar 2026 | $3.92M | — | — | 1.2% | |
| Jun 2026 | $0 | -100.0% | +159.7% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MIRM) | $5.49M | -13.6% | +17.0% | 1.2% | |
Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.34M | 28M | 286.33M | 222.5M | 296.68M |
| Short-term Investments | 125.2M | 123.72M | 0 | 57.81M | 86.64M |
| Net Receivables | 4.37M | 23.99M | 67.97M | 78.29M | 123.33M |
| Inventory | 1.51M | 5.57M | 22.31M | 22.4M | 24.89M |
| Other Current Assets | 4.17M | 8.95M | 10.94M | 11.78M | 18.14M |
| Total Current Assets | 166.59M | 190.23M | 387.54M | 392.79M | 549.68M |
| Property, Plant & Equipment (Net) | 2.55M | 2.35M | 1.99M | 9.81M | 10.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 18.74M | 58.95M | 252.93M | 249.82M | 260.92M |
| Long-term Investments | 4.98M | 0 | 0 | 12.53M | 8.11M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 101.79M | 101.38M | 4.17M | 5.81M | 13.5M |
| Total Non-current Assets | 128.06M | 162.68M | 259.08M | 277.97M | 293.13M |
| Total Assets | 294.65M | 352.91M | 646.62M | 670.75M | 842.81M |
| Account Payables | 9.17M | 8.69M | 7.42M | 14.62M | 9.61M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.98M | 15.75M | 20.94M | 32.25M | 47.28M |
| Total Current Liabilities | 42.6M | 64.73M | 87.06M | 126.55M | 205.8M |
| Long-term Debt | 0 | 0 | 306.42M | 308.08M | 309.8M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 129.92M | 140.35M | 0 | 0 | 0 |
| Other Non-current Liabilities | 17K | 4.53M | 3.85M | 2.51M | 5.01M |
| Total Non-current Liabilities | 131.84M | 146.14M | 310.89M | 318.56M | 322.32M |
| Total Liabilities | 174.44M | 210.87M | 397.95M | 445.11M | 528.12M |
| Common Stock | 3K | 4K | 5K | 5K | 5K |
| Retained Earnings | (257.16M) | (392.82M) | (556.24M) | (644.18M) | (667.54M) |
| Accumulated OCI | (35K) | (217K) | 1.64M | (373K) | 351K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 120.21M | 142.04M | 248.67M | 225.64M | 314.69M |
| Total Debt | 2.61M | 2.19M | 308.14M | 317.76M | 319.45M |
| Net Debt | (28.73M) | (25.82M) | 21.82M | 95.26M | 22.77M |
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
Intrinsic Alpha fair value
Locked
Current Price
$92.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.